Skip to main content
SpringerLink
Log in

Mometasone/Formoterol Inhalation Aerosol

In Asthma Uncontrolled on Medium- or High-Dose Inhaled Corticosteroids

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The corticosteroid mometasone and the long-acting β2-selective adrenoreceptor agonist formoterol have been combined in a single pressurized metered-dose inhaler for use in patients aged ≥12 years with asthma.

In a 26-week well designed trial in patients with persistent asthma uncontrolled on medium-dose inhaled corticosteroids (ICS), mometasone/formoterol 200 μg/10 μg twice daily (bid) was more effective than placebo or the same nominal dosage of formoterol alone in reducing the incidence of asthma deteriorations, as well as in improving lung function, asthma control, asthma symptoms and asthma-related quality-of-life outcomes. The combination was also more effective than the same nominal dosage of mometasone alone in improving lung function and asthma control.

Similarly, in a 12-week well designed trial in patients with persistent asthma uncontrolled on high-dose ICS, mometasone/formoterol 400μg/10μg bid was more effective than the same nominal dosage of mometasone alone in improving lung function, asthma control and asthma symptoms. Treatment with a lower dosage of the combination (200μg/10μg bid) yielded similar results and, moreover, significantly reduced the incidence of asthma deteriorations compared with mometasone alone.

Mometasone/formoterol was generally well tolerated in clinical trials of 12–52 weeks’ duration. The adverse event profile of the combination was consistent with that of its individual components; no new or unexpected safety signals were detected.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Fig. 2
Table III

Similar content being viewed by others

References

  1. Fanta CH. Asthma. N Engl J Med 2009; 360 (10): 1002–9

    Article  CAS  PubMed  Google Scholar 

  2. World Health Organisation. Asthma fact sheet no. 307 [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs307/en/index.html [Accessed 2011 Sep 27]

  3. Global Initiative for Asthma. Global burden of asthma™ [online]. Available from URL: http://www.ginasthma.org/uploads/users/files/backgrounder-20.pdf [Accessed 2010 Nov 22]

  4. National Heart LaBI. US Department of Health and Human Services. National Asthma Education and Prevention Program. Expert Panel report 3: guidelines for the diagnosis and management of asthma. Summary report 2007 [online]. Available from URL: http://www.nhlbi.nih.gov/guidelines/asthma/asthsumm.pdf [Accessed 2010 Nov 22]

  5. Blair R, Breit JS, Peters SP. The Merck Manuals Online Medical Library: asthma [online]. Available from URL: http://www.merckmanuals.com/home/sec04/ch044/ch044a.html [Accessed 2011 Sep 27]

  6. Papiris SA, Manali ED, Kolilekas L, et al. Acute severe asthma: new approaches to assessment and treatment. Drugs 2009; 69 (17): 2363–91

    Article  CAS  PubMed  Google Scholar 

  7. Fuhlbrigge AL, Adams RJ, Guilbert W, et al. The burden of asthma in the United States. Am J Resp Crit Care Med 2002; 166: 1044–9

    Article  PubMed  Google Scholar 

  8. Chung KF, Caramori G, Adcock IM. Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol 2009 Sep; 65 (9): 853–71

    Article  CAS  PubMed  Google Scholar 

  9. Postma DS, Kerstjens HA, ten Hacken NH. Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?. Naunyn Schmiedeberg Arch Pharmacol 2008; 378 (2): 203–15

    Article  CAS  Google Scholar 

  10. Frois C, Wu EQ, Ray S, et al. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. Clin Ther 2009 Dec; 31 (12): 2779–803

    Article  CAS  PubMed  Google Scholar 

  11. Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs 2001; 61 (9): 1325–50

    Article  CAS  PubMed  Google Scholar 

  12. Faulds D, Hollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic potential in reversible obstructive airway disease. Drugs 1991; 42 (1): 115–37

    Article  CAS  PubMed  Google Scholar 

  13. Goldsmith DR, Keating GM. Budesonide/formoterol: a review of its use in asthma. Drugs 2004; 64 (14): 1597–618

    Article  CAS  PubMed  Google Scholar 

  14. Affrime MB, Cuss F, Padhi D, et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 2000; 40: 1227–36

    CAS  PubMed  Google Scholar 

  15. Affrime MB, Kosoglou T, Thonoor CM, et al. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest 2000; 118: 1538–46

    Article  CAS  PubMed  Google Scholar 

  16. Lecaillon JB, Kaiser G, Palmisano M, et al. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via aerolizer™. Eur J Clin Pharmacol 1999; 55: 131–8

    Article  CAS  PubMed  Google Scholar 

  17. Fan Y, Zhao L, Roy P. NDA22-518: clinical pharmacology review [online]. Available from URL: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM224594.pdf [Accessed 2011 Sep 27]

  18. Asmanex Twisthaler 110mcg,220mcg(mometasonefuroate inhalation powder): US prescribing information. Kenilworth (NJ): Schering Corporation, a subsidiary of Schering-Plough Corporation, 2010

  19. Foradil® Aerolizer® (formoterol fumarate inhalation powder): US prescribing information. Kenilworth (NJ): Schering Corporation, 2002

  20. Dulera® 100mcg/5mcg (mometasone furoate 100mcg and formoterol fumarate dihydrate 5 mcg) inhalation aerosol; Dulera® 200 mcg/5 mcg (mometasone furoate 200 mcg and formoterol fumarate dihydrate 5 mcg) inhalation aerosol: US prescribing information. Whitehouse (NJ): Schering Corporation, a subsidiary of Merck & Co., Inc., 2010

  21. Maspero JF, Nolte H, Cherrez-Ojeda I, et al. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma. J Asthma 2010; 47: 1106–15

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Weinstein SF, Corren J, Murphy K, et al. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10μg and 400/10μg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids. Allergy Asthma Proc 2010; 31 (4): 280–9

    Article  CAS  PubMed  Google Scholar 

  23. Nathan RA, Nolte H, Pearlman DS. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 μg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc 2010; 31 (4): 269–79

    Article  CAS  PubMed  Google Scholar 

  24. Meltzer EO, Kuna P, Nolte H, et al. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. Eur Respir J. Epub 2011 Aug 4

  25. Weinstein SF, Nathan RA, Nolte H. Combined mometasone furoate/formoterol reduces asthma deteriorations in patients with persistent asthma uncontrolled on medium-or high-dose inhaled corticosteroids [abstract no. P89]. Ann Allergy Asthma Immunol 2010 Nov; 105 (5 Suppl. 1): A51-2

  26. White M, Meltzer EO, Nathan RA, et al. Improved asthma control with mometasone furoate/formoterol: a new combination treatment for persistent asthma [abstract no. P83]. Ann Allergy Asthma Immunol 2010 Nov; 105 (5 Suppl. 1): A49-50

    Google Scholar 

  27. Murphy K, Meltzer EO, Nathan RA, et al. Quality of life improvements in persistent asthma subjects receiving combined mometasone furoate and formoterol [abstract no. P88]. Ann Allergy Asthma Immunol 2010 Nov; 105 (5 Suppl. 1): A51

  28. Nolte H, Maspero J, Cherrez Ojeda I. The safety and tolerability characteristics of mometasone furoate/formoterol (MF/F) combination therapy in patients with persistent asthma: findings from the MF/F phase III clinical development program [abstract no. 275 plus poster]. 75th Annual International Scientific Assembly of the American College of Chest Physicians; 2009 31 Oct–5 Nov; San Diego (CA)

  29. Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteriods for treating asthma. N Engl J Med 2011 Jun 30; 364 (26): 2473–5

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    James E. Frampton

Authors
  1. James E. Frampton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James E. Frampton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frampton, J.E. Mometasone/Formoterol Inhalation Aerosol. Drugs 72, 1229–1241 (2012). https://doi.org/10.2165/11206920-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11206920-000000000-00000

Keywords

Search

Navigation